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Abstract
Context: Recent whole genome mRNA expression profiling studies revealed that bladder
cancers can be grouped into molecular subtypes, some of which share clinical properties
and gene expression patterns with the intrinsic subtypes of breast cancer and the
molecular subtypes found in other solid tumors. The molecular subtypes in other solid
tumors are enrichedwith specificmutations and copynumber aberrations that are thought
to underlie their distinct progression patterns, and biological and clinical properties.
Objective: The availability of comprehensive genomic data from The Cancer Genome
Atlas (TCGA) and other large projects made it possible to correlate the presence of DNA
alterations with tumor molecular subtype membership. Our overall goal was to deter-
mine whether specific DNA mutations and/or copy number variations are enriched in
specific molecular subtypes.
Evidence: [1_TD$DIFF]We used the complete TCGA RNA-seq dataset and three different published
classifiers developed by our groups to assign TCGA’s bladder cancers to molecular
subtypes, and examined the prevalence of the most common DNA alterations within
them. We interpreted the results against the background of what was known from the
published literature about the prevalence of these alterations in nonmuscle-invasive
and muscle-invasive bladder cancers.
Evidence synthesis: The results confirmed that alterations involving RB1 and NFE2L2
were enriched in basal cancers, whereas alterations involving FGFR3 and KDM6A were
enriched in luminal tumors.
Conclusions: The results further reinforce the conclusion that themolecular subtypes of
bladder cancer are distinct disease entities with specific genetic alterations.
Patient summary: Our observation showed that some of subtype-enriched mutations
and copy number [6_TD$DIFF]aberrations are clinically actionable, which has direct implications for
the clinical management of patients with bladder cancer.
soc# 2017 European As* Corresponding author. Johns Hopkins Greenberg Bladder Cancer Institute, 600 Wolfe Street,
Marburg 149, Baltimore, MD 21287-2101, USA.
nkey@jhmi.edu (D.J. McConkey).E-mail address: djmccohttp://dx.doi.org/10.1016/j.eururo.2017.03.010
0302-2838/# 2017 European Association of Urology. Published by Elsevieriation of Urology. Published by Elsevier B.V. All rights reserved.B.V. All rights reserved.
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Recent whole genome mRNA expression profiling studies
revealed that bladder cancers can be grouped into molecu-
lar subtypes, some of which share clinical properties and
gene expression patterns with the intrinsic subtypes of
breast cancer and the molecular subtypes found in other
solid tumors. The molecular subtypes in other solid tumors
are enriched with specific mutations and copy number
aberrations (CNAs) that are thought to underlie their
distinct progression patterns, and biological and clinical
properties.
2. Evidence acquisition
We used the complete The Cancer Genome Atlas (TCGA)
RNA-seq dataset and three different published classifiers
developed by our groups to assign TCGA’s bladder cancers
to molecular subtypes, and examined the prevalence of the
most common DNA alterations within them (Supplemen-
tary material). We interpreted the results against the
background of what was known from the published
literature about the prevalence of these alterations in
nonmuscle-invasive and muscle-invasive bladder cancers.
3. Evidence synthesis
3.1. Clinical issues in bladder cancer
Clinical experience and emerging genomic data support the
idea that bladder cancers progress along two largely
nonoverlapping tracks (‘‘papillary’’ and ‘‘nonpapillary’’)
that pose distinct challenges for clinical management [1–
3]. Most nonmuscle-invasive bladder cancers (NMIBCs)
belong to the papillary pathway and are characterized by
the presence of activating type-3 receptor for fibroblast
growth factor (FGFR3) mutations, downstream Ras pathway
activation, wild-type TP53, and stable genomes [1–3]. Clini-
cally, papillary NMIBCs are rarely lethal but recur almost
always, necessitating that patients receive lifelong surveil-
lance; the repeated surgical procedures required to deal
with recurrences cause significant anxiety, discomfort, and
morbidity, making bladder cancer the most expensive
tumor on a per patient basis. A significant proportion of
cases (15–20%) of NMIBCs progress to become muscle
invasive [1,2]. However, currently no reliable tools are
available to identify them before they become life
threatening. The nonpapillary pathway is characterized
by loss-of-function mutations and CNAs involvingTP53 and
RB1 and genomic instability [1,2]. It gives rise to aggressive,
muscle-invasive bladder cancers (MIBCs), representing
approximately 20–25% of all bladder cancers and causing
death in approximately half of affected patients. Carcinoma
in situ (CIS) is generally considered to be the precursor
lesion for nonpapillary MIBCs [1,2], but comprehensive
genomic data for CIS are not yet available, so this
assumption awaits direct experimental validation. Patients
with either high-grade papillary nonmuscle-invasive dis-
ease or CIS are currently treated with the same adjuvanttherapy (intravesical Bacillus Calmette–Guerin [BCG] im-
munotherapy), but it is by no means clear that BCG
produces comparable benefit in CIS and high-grade papil-
lary tumors [1,2]. Many high-grade papillary tumors
ultimately become BCG unresponsive, so clinicians are
then faced with the dilemma of whether to continue using a
bladder-sparing regimen or to employ definitive surgery.
The latter is certainly too aggressive for those patients
whose tumors could be controlled by local therapy, but
again there are no reliable tools to distinguish the tumors
that have the potential to metastasize from those that do
not. Muscle-invasive disease is managed with definitive
local therapy (chemoradiation) or surgery (cystectomy)
with or without perioperative systemic cisplatin-based
chemotherapy to treat subclinical metastatic disease, but it
is still not possible to distinguish the patients who warrant
chemotherapy from those who will not benefit from it. It
would also be tremendously useful to have biomarkers that
would enable patients and their physicians to choose
between bladder-sparing regimens such as chemoradiation
and cystectomy. Overall, it is hoped that by understanding
the molecular mechanisms that give rise to papillary and
nonpapillary bladder cancers, it will be possible to develop
methods to inform clinical decision making at every step of
disease progression and management.
3.2. Intrinsic subtypes of cancer
The widespread use of genomics to investigate cancer
heterogeneity is transforming our understanding of cancer
biology. A pioneering study in leukemia demonstrated that
mRNA expression profiling could be used to distinguish ALL
from AML with a high degree of accuracy [4], and a
subsequent study used gene expression profiling to identify
two previously unrecognized molecular subtypes of diffuse
large B-cell lymphoma [5]. Importantly, patients whose
tumors belonged to one of the subtypes (‘‘germinal center-
like DLBCL’’) had better clinical outcomes than patientswith
the other (‘‘activated B-like DLBCL’’) [5]. Parallel studies in
breast cancer revealed that they could also be grouped into
‘‘intrinsic subtypes’’ that had very different biological
properties and behaved clinically as distinct disease entities
[6,7]. Patients with basal-like or HER2-enriched breast
tumors had poor clinical outcomes in the absence of
systemic therapy, but many of them benefited greatly from
neoadjuvant chemotherapy (NAC) [[7_TD$DIFF]8,9]. Patients with
HER2-enriched tumors also obtained significant clinical
benefit from ERBB2 antagonists [[8_TD$DIFF]10]. In the absence of
perioperative chemotherapy, women with luminal tumors
had better prognoses [ [9_TD$DIFF]11] and, when given perioperative
chemotherapy, most patients also obtained little to no
benefit [ [10_TD$DIFF]8,12]. Rather, they obtained major chemopreven-
tive clinical benefit from adjuvant therapy with selective
estrogen receptor modulators (SERMs), which reduced
disease recurrence by about 50% [[9_TD$DIFF]11]. In contrast, SERMs
produced no benefit in patients with basal-like or HER2-
enriched tumors [[9_TD$DIFF]11]. Subsequent studies identified molec-
ular subtypes in head and neck squamous cell carcinomas
(SCCs) [ [11_TD$DIFF] 3], glioblastomas [ [12_TD$DIFF] 4], and pancreatic cancers [[13_TD$DIFF] 5],
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subtypes that cut across cancer types [ [14_TD$DIFF] 6]. The potential
clinical significance of the molecular subtypes of these
cancers is being investigated.
3.3. DNA alterations in bladder cancers
The recently completed TCGAMIBC (BLCA) project produced
a comprehensive, open-access catalog of DNA alterations in a
cohort of over 400 MIBCs. The first TCGA ‘‘bladder cancer
study’’ reported the results of a comprehensive integrated
genomic analysis of131 tumors [[15_TD$DIFF] 7], and a recent review
article provided an update on 238 tumors [[5_TD$DIFF]18]. These initial
results were also incorporated into a pan-cancer analysis
that compared the genomic features of 12 different types of
cancers [[14_TD$DIFF] 6]. Furthermore, a thorough review of the different
genomic alterations that characterize low-grade papillary
tumors (Ta) and MIBCs was also published recently
[1]. Finally, a recent paper reported the comprehensive
transcriptional analysis of a cohort of 460 patients with
NMIBC [[16_TD$DIFF] 9]. Therefore, excellent, comprehensive summaries
of the major genomic alterations in the complete spectrum
of bladder cancers can be found elsewhere. The key findings
will now be summarized briefly.
3.3.1. Major drivers of mutagenesis
Cigarette smoking is an established risk factor for bladder
cancer [2], and chronic exposure to cigarette smoke-like
nitrosamines (ie, BBN) causes bladder cancer in rodents
[[17_TD$DIFF]20]. Aromatic compounds in cigarette smoke produce DNA
damage, so it was expected that a history of cigarette
smoking would be associated with specific tobacco-related
DNA mutations in TCGA exome sequencing data. Analyses
of the initial TCGA cohort of 131 tumors failed to identify
such signatures, although tumors from smokers were
enriched with specific DNA methylation patterns
[[15_TD$DIFF] 7]. Interestingly, a significant number of bladder cancers
contained mutations in NFE2L2 (NRF2) and TXNIP [[5_TD$DIFF]18]
genes, which encode proteins that inhibit the damaging
effects of the reactive oxygen species that are produced in
response to cigarette smoke carcinogens. Although there
was no obvious relationship between the NFE2L2 and/or
TXNIP alterations and smoking status in bladder cancers,
mutations in these genes were enriched in lung and head
and neck cancers from smokers [ [18_TD$DIFF]21,22], suggesting poten-
tial causal roles in carcinogenesis and/or tumor progression.
A more recent reanalysis of the original TCGA cohort
identified a novel DNA mutational signature associated
with inactivating mutations in the gene encoding the
nucleotide excision repair protein, ERCC2, and established
that these signatures were enriched in tumors from
smokers [ [19_TD$DIFF]23]. Importantly, the signature was much more
strongly associated with ERCC2 inactivation than it was
with smoking, suggesting that the former was the driving
force underlying the signature [[19_TD$DIFF]23].
The APOBEC family of antiviral enzymes promotes
cytosine deamination and mutagenesis of single-stranded
DNA and mRNAs. Among the APOBEC genes, APOBEC3B
appears to be most commonly overexpressed in solidtumors, and bladder cancers stand out for expressing some
of the highest levels of APOBEC3B among all solid
malignancies [[20_TD$DIFF] 4]. Aside from being upregulated by infec-
tion, APOBEC3B activity can also be increased by chemical
carcinogens, which promote APOBEC3B-mediatedmutagen-
esis by inducing the formation of the single-strand DNA
intermediates that are formed during DNA damage and
repair [[20_TD$DIFF] 4]. Analyses of mutational patterns have revealed
that a large proportion of the total mutational burden in
bladder cancer is attributable to APOBEC3B-mediated
mutagenesis [[21_TD$DIFF] 7,24,25], and the prevalence of APOBEC3B-
associated mutations increased with subclonal evolution in
lung cancers [[22_TD$DIFF] 4,26]. Furthermore, it was recently found that
an APOBECmutation signature was significantly enriched in
high-risk NMIBCs [[16_TD$DIFF] 9]. Taken together, accumulating data
suggest that APOBEC-mediated mutations may play a
central causative role in driving bladder cancer genomic
heterogeneity and disease progression.
3.3.2. Major targets of DNA alterations
Histone modifications play central roles in the regulation of
gene expression, and whole exome sequencing studies
revealed that mutations in chromatin-modifying enzymes
were extremely common in bladder cancers [ [23_TD$DIFF] 7]. Among
them, inactivating mutations in the histone H3 lysine 27
(H3K27) demethylase KDM6A (also known as UTX) were
most common and enriched in NMIBCs (32–43%) [ [24_TD$DIFF]18,27],
whereas inactivating mutations in the SET family histone
H3 lysine 4 (H3K4) methyltransferase MLL2 were more
common in MIBCs (19%) [ [5_TD$DIFF]18], and mutations in KDM6A and
MLL2were mutually exclusive [[5_TD$DIFF]18]. Although the biological
consequences of these events have not been defined
experimentally, they would be expected to lead to
decreased RNA polymerase accessibility, gene silencing,
and a less well-differentiated phenotype. In-depth chroma-
tin immunoprecipitation/sequencing (ChIP-seq) studies are
required to directly address this hypothesis.
As introduced above, one of the most striking differences
betweenNMIBCs andMIBCs is the relative frequency of TP53
gene inactivation and relative levels of genomic instability.
Overall, mutations in TP53 were observed in about 50% of
MIBCs but were less common in NMIBCs (20% of tumors)
[[25_TD$DIFF]1,28–[26_TD$DIFF]30]. Interestingly, 85% of high-grade NMIBCs (T1G3)
contained p53 pathway alterations [[27_TD$DIFF]31]. Furthermore, am-
plification of TP53’s inhibitor, MDM2, occurred in approxi-
mately 9% of MIBCs [[28_TD$DIFF]1,18], indicating that TP53 inactivation
occurred in the majority of muscle-invasive tumors. RB1
inactivation was also much more common in MIBCs as
compared with that in NMIBCs [[5_TD$DIFF]18], and mutations in RB1
tended to be associated with mutations in TP53
[[5_TD$DIFF]18]. Interestingly, the same patterns were not observed
with RB1’s upstream inhibitor (CDKN2A), which was deleted
in approximately equal numbers of NMIBCs andMIBCs (50%)
[1]. Dysregulation of other genes that promote cell cycle
progression was also common in bladder cancers. Amplifi-
cation of cyclin D1 was reported in approximately 20% of
NMIBCs and MIBCs [1], and amplification of E2F3 was
observed in high-grade T1 lesions andMIBCs [[29_TD$DIFF]1,32]. An early
study reported that MYC amplification was associated with
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studies, MYC amplification was observed in about 13% of
MIBCs [[5_TD$DIFF]18].
Inactivating mutations in genes encoding DNA repair
proteins were also relatively common inMIBCs [[31_TD$DIFF] 7,34]. The
most prevalent were inactivating mutations in ERCC2 (12%
of tumors) [ [5_TD$DIFF]18], which were linked to sensitivity to
neoadjuvant cisplatin-based combination chemotherapy
[ [32_TD$DIFF] 5]. Inactivating mutations in several other DNA repair
proteins were also linked to cisplatin sensitivity [[33_TD$DIFF] 6].
Inactivating mutations in STAG2, a component of the
cohesin complex that functions in chromosome segrega-
tion, were common in NMIBCs and MIBCs [ [34_TD$DIFF] 4,37–[35_TD$DIFF]40], but
their biological significance remains unclear; the canonical
role of the cohesin complex would suggest that inactivation
of STAG2 should produce genomic instability, but the
significant enrichment of STAG2 mutations in low-grade
tumors that largely lack aneuploidy [[35_TD$DIFF]40] argues against this
being their most relevant effect in bladder cancers [[34_TD$DIFF] 4,37–
[35_TD$DIFF]40]. Alternative mechanisms include alterations in high-
order chromatin organization and gene expression.
Activating mutations in the telomerase (TERT1) promot-
er were common in both NMIBCs and MIBCs [ [36_TD$DIFF]41–[37_TD$DIFF]48],
making them attractive biomarkers for early detection of
recurrence [ [38_TD$DIFF]44,45] and potentially as therapeutic targets
across the course of disease progression.
Bladder cancers often contained DNA alterations involv-
ing oncogenes or tumor suppressor genes that regulate
activation of the Ras–MEK–ERK and PI3 kinase–AKT–mTOR
pathways. These pathways control progression through the
RB1-dependent G1-S cell cycle restriction point, anabolic
metabolism, and cell survival. Activating mutations in
FGFR3 were detected in up to 80% of NMIBCs and
approximately 15–20% of MIBCs, consistent with earlier
studies [[39_TD$DIFF]1,49,50]. Preclinical studies demonstrated that
these FGFR3 mutations, which cause constitutive receptor
activation, functioned to promote proliferation via down-
stream activation of the ERKs [ [40_TD$DIFF]51,52]. Papillary and
nonpapillary cancers contained similar frequencies of
activating RAS mutations (5–10%) [ [41_TD$DIFF]51], which also function
to promote downstream ERK activation. RAS and FGFR3
mutations occurred in a mutually exclusive fashion [ [5_TD$DIFF]18], so
together they probably accounted for enhanced ERK
activation in almost 90% of NMIBCs. Although activating
FGFR3 mutations were less common in MIBCs, some MIBCs
contained activating FGFR3 fusions [ [42_TD$DIFF]53]. They also con-
tained activating mutations, fusions, or amplification of
genes encoding members of the epidermal growth factor
receptor (EGFR) family [[15_TD$DIFF] 7], including the EGFR itself (about
10% of tumors), ERBB2 (about 10% of tumors), ERBB3 (about
10% tumors), and ERBB4 (about 6% of tumors). Other tumors
contained inactivating mutations in the RAS inhibitor, NF1
(over 10%) [ [28_TD$DIFF]1,18]; so, together, these alterations probably
promoted RAS pathway activation in over 50% of MIBCs.
With respect to the PI3 kinase/AKT pathway, activating
PIK3CA mutations—predominantly in the region coding for
the helical domain, probably caused by APOBEC3B-mediat-
ed mutagenesis [[20_TD$DIFF] 4]—were common in both NMIBCs and
MIBCs. Amplification of AKT3 or inactivating mutations invarious negative regulators of the PI3 kinase/AKT/mTOR
pathway (including the lipid phosphatase PTEN) were also
observed, leading to predicted pathway activation in almost
75% of MIBCs [ [28_TD$DIFF]1,18].
Mutations and/or amplification of transcription factors
implicated in urothelial terminal differentiationwere found
in MIBCs [ [5_TD$DIFF]18]. Amplifications of peroxisome proliferator
activator receptor-gamma (PPARG), GATA3, and SOX4 were
frequently detected, occurring in about 10–15% of tumors
[[5_TD$DIFF]18]. Mutations in ELF3, RXRA, and KLF5were also relatively
common, occurring in 5–10% of tumors [ [5_TD$DIFF]18]. Mutations in
FOXA1were observed in about 5% of tumors, and deletion of
FOXQ1 occurred in about 10% of tumors [ [5_TD$DIFF]18]. Inactivating
mutations in NOTCH1 and NOTCH2 have also been reported
in MIBCs [ [43_TD$DIFF]54], and preclinical studies in mouse models
suggested that they promoted tumor progression by
facilitating epithelial-to-mesenchymal transition (EMT)
[[44_TD$DIFF]55]. Finally, mutations in the ubiquitin ligase and NOTCH
pathway regulator, FBXW7, occurred in about 7% of MIBCs
[[5_TD$DIFF]18]. Although inactivating mutations in other develop-
mental pathways were less common, preclinical studies
have suggested that activation of the Wnt/b-catenin
pathway and downregulation of the sonic hedgehog
pathway also contribute to bladder cancer progression
[[45_TD$DIFF] 6,57].
3.4. Molecular subtypes of bladder cancer
The identification and validation of molecular subtypes in
other malignancies provided the impetus to use transcrip-
tome profiling to search for molecular subtypes in bladder
cancers. The initial results established that unsupervised
analyses of gene expression could distinguish most NMIBCs
from most MIBCs [ [46_TD$DIFF]58– [47_TD$DIFF]60]. Furthermore, early studies of
NMIBCs identified gene expression signatures associated
with disease aggressiveness using unsupervised analyses
[[48_TD$DIFF]61– [49_TD$DIFF]63]. These studies showed the first indications of the
presence of major molecular subtypes in bladder cancer
[[50_TD$DIFF]19,64]. One of our groups (M.H., Lund University, Lund,
Sweden) extended these findings by implicating differences
in[51_TD$DIFF] TP53 mutation frequencies and/or genomic instability to
the formation of these two major gene expression subtypes
[[52_TD$DIFF] 8]. Subsequently, they used a large cohort of NMIBCs and
MIBCs (n = 308) to identify additional subtypes within the
two major clusters [[53_TD$DIFF]65]. The Lund classification revealed
that bladder cancers could be segregated into at least five
molecular subtypes, termed urobasal A (uroA), urobasal B
(uroB), genomically unstable (GU), infiltrated, and SCC like
(SCCL) [ [53_TD$DIFF]65]. The uroA and uroB tumors were characterized
by stratified expression of differentiation-associated bio-
markers reminiscent of what is observed in the normal
urothelium, whereas differentiation-associated biomarkers
displayed abnormal expression in the GU and SCCL tumors.
The SCCL subtype was characterized by expression of
squamous keratins (KRT5, KRT6, and KRT14) and keratini-
zation-associated genes [ [54_TD$DIFF]66], and the SCCL and uroB tumors
were both enriched with various degrees of squamous
differentiation markers [ [55_TD$DIFF]65,66]. As its name implies, the
infiltrated subtype was characterized by the expression of
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Analysis of a large cohort of 460 tumors recently
identified three distinct subtypes (Classes 1–3) in NMIBC
[[16_TD$DIFF] 9] The study validated previously observed subgroups in
NMIBC and identified a new subtype (Class 3) that showed
basal-like characteristics and pronounced expression of
lncRNAs. Mutations were called from RNA-seq data, which
have potential limitations. Frequent mutations were
observed in genes encoding proteins involved in chromatin
organization and cytoskeletal functions. Furthermore, high-
risk tumors (Class 2) were enriched for mutations in, for
example, TP53 and ERBB2, and for APOBEC-related muta-
tions. The observation of enrichment for APOBEC-related
mutations in high-risk NMIBCs indicates that APOBEC may
drive disease progression in NMIBC.
Other groups performed independent studies to identify
molecular subtypes in cohorts ofMIBC [[56_TD$DIFF]17,67,68]. A group led
by one of us (W.K., University ofNorth Carolina [UNC], Chapel
Hill, NC, USA) assembled a meta-dataset of 262 high-grade
tumors from four previously published cohorts for discovery
and created a new dataset from 49 tumors collected at
Memorial Sloan Kettering Cancer Center for validation. Using
consensus clustering, they identified twomolecular subtypes
of MIBC in both datasets [[57_TD$DIFF]68]. The genes that distinguished
the two clusters had previously been implicated in urothelial
differentiation and overlapped substantially with the genes
that distinguished the basal-like and luminal intrinsic
subtypes of breast cancer, leading the UNC investigators to
name their MIBC subtypes ‘‘basal like’’ and ‘‘luminal’’ [[57_TD$DIFF]68]. In
parallel, another of our groups (W.C. and D.J.M., University of
TexasMDAnderson Cancer Center, Houston, TX USA) created
twowhole transcriptome datasets (n = 73 and n = 57 tumors)
and used unsupervised hierarchical clustering to identify
three candidate subtypes [[58_TD$DIFF]67]. The MD Anderson group also
noted that the genes that characterized two of the subtypes
were similar to the ones that distinguished basal-like and
luminal breast cancers, prompting them to term them ‘‘basal’’
and ‘‘luminal’’ [[58_TD$DIFF]67]. The group’s third subtype was distin-
guished from the other two by stromal biomarkers and an
active p53 gene expression signature, so they termed it ‘‘p53-
like’’ [[58_TD$DIFF]67]. Finally, TCGA used a combination of different
approaches to identify four molecular subtypes in an RNA-
seq dataset generated from 129 tumors [[15_TD$DIFF] 7]. Although TCGA
discussed whether or not to name them ‘‘basal’’ and
‘‘luminal’’ in the first marker paper, they settled on a more
conservative approach and termed them ‘‘clusters I–IV’’ but
discussed their similarities to the intrinsic subtypes of breast
cancer [[15_TD$DIFF] 7]. In addition, TCGA noted that cluster I was
enrichedwith tumors having papillary features and cluster III
with tumors having squamous features, inspiring the labels
‘‘papillary’’ and ‘‘squamous,’’ respectively [[15_TD$DIFF] 7]. As introduced
above, a group based at the Broad Institute then repeated the
exercise on an interim expanded cohort of 238 tumors and
largely reproduced their original data [[5_TD$DIFF]18]. They renamed the
clusters ‘‘basal,’’ ‘‘immune undifferentiated,’’ ‘‘luminal im-
mune,’’ and ‘‘luminal’’ to reflect the dominant features they
found in the gene expression signatures that defined each
subtype [[5_TD$DIFF]18].Parallel efforts attempted to reconcile the molecular
subtypes identified by the groups using shared whole
transcriptome datasets [ [59_TD$DIFF]69– [60_TD$DIFF]71]. The results of this work
revealed a significant overlap among the subtype calls. The
most upstream division occurred at the level of the basal
versus luminal bifurcation proposed by the group at UNC
[ [59_TD$DIFF]69– [60_TD$DIFF]71]. The other subtypes appeared to mostly represent
subdivisions of these subtypes. The MD Anderson p53-like
subtype, which shared similarities with the Lund infiltrated
subtype [[53_TD$DIFF]65], TCGA’s original cluster II [[15_TD$DIFF] 7], and the updated
TCGA ‘‘immune undifferentiated’’ and ‘‘luminal immune’’
subtypes [ [5_TD$DIFF]18], consisted of a mixture of basal and luminal
tumors that were heavily infiltrated with stromal cells, and
the Lund uroA and GU tumors largely corresponded to UNC
luminal tumors. Although the uroB tumorswere assigned to
the basal subtypes identified by other groups, the Lund
group recognized that the uroB tumors contained FGFR3
pathway gene expression signatures and were enriched
with activating FGFR3 mutations, and concluded that they
probably corresponded to progressed uroA tumors [[53_TD$DIFF]65].
Subtype membership had important implications for
clinical outcomes. Similar to basal-like breast cancers [7], the
Lund SCCL and uroB tumors and the squamous/basal tumors
identified by the groups atUNC,MDAnderson Cancer Center,
and TCGA were aggressive, and associated with advanced
stage and metastatic disease at presentation, squamous
histopathological features, and shorter survival in the
absence of neoadjuvant cisplatin-based combination che-
motherapy [[61_TD$DIFF] 7,65,67,68,72]. However, about half of basal
tumorswere downstaged by NAC [[58_TD$DIFF]67], and early preliminary
data suggested that the overall benefit provided by NAC
might be greatest in patients whose tumors belonged to the
basal molecular subtype [[62_TD$DIFF]73]. If these preliminary data are
confirmed in larger and more mature clinical datasets, the
results would be reminiscent of past experience in breast
cancer, where NAC has produced the greatest benefit in
patients with highly proliferative basal-like (and HER2-
enriched) tumors [[10_TD$DIFF]8,12]. Although the molecular mecha-
nisms that underlie the benefit produced by chemotherapy
in basal tumors are still under investigation, basal human
bladder cancer cell lines are more sensitive to cisplatin-
induced apoptosis than are luminal cell lines (A. Ochoa, D.J.
McConkey, unpublished observations). Conversely, NAC
produced less clinical benefit in patients whose tumors
belong to the infiltrated/p53-like subtype in the clinical trials
that have been performed to date [[63_TD$DIFF] 7,73].
The variable levels of immune cell infiltration observed
in the bladder cancer subtypes [[5_TD$DIFF]18] suggested that patients
with these tumors might derive different amounts of
benefit from immunotherapies [[64_TD$DIFF]74]. Consistent with these
predictions, early results suggest that TCGA subtype
membership may be an independent predictor of benefit
from therapy with the anti-PDL1 antibody atezolizumab
[ [65_TD$DIFF]75]. In the phase II trial that led to Food and Drug
Administration approval of the drug, patientswhose tumors
belonged to TCGA cluster II obtained somewhat more
benefit than patients whose tumors belonged to the other
subtypes, and patients with ‘‘papillary’’ (cluster I) tumors
derived little benefit, if at all [ [65_TD$DIFF]75]. Importantly, immune
[(Fig._1)TD$FIG]
Fig. 1 – Comparison of subtype calls in TCGA’s final dataset. Each group used TCGA’s normalized RNA-seq data to assign TCGA’s tumors to the UNC, MD
Anderson, or Lund subtypes. Published calls made by a group at The Broad Institute [[5_TD$DIFF]18] and TCGA were also included for comparison. The top left
panel provides a schematic overview of the relationships among the calls made by the five groups. The heat maps display the relative expression of
the gene sets that characterize each group’s subtypes. The red and green colors correspond to high and low relative expression, respectively.
GU = genomically unstable; MDA = MD Anderson; NA = not applicable; SCCL = squamous cell carcinoma like; TCGA = The Cancer Genome Atlas;
UNC = University of North Carolina; uroA = urobasal A; uroB = urobasal B.
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E U RO P E AN URO LOG Y 7 2 ( 2 0 1 7 ) 3 5 4 – 3 6 5360infiltration and tumor PDL1 expression are actually highest
in TCGA cluster IV, which corresponds to a subset of
‘‘mesenchymal’’ basal tumors [[66_TD$DIFF]76], and this connection
between EMT and immune infiltration and tumor PDL1
expressionwas observed across solid tumors in a recent pan-
cancer analysis [[67_TD$DIFF] 7]. Therefore, even though TCGA cluster IV
tumors are heavily infiltrated with lymphocytes, the T cells
appear to bemore actively suppressed than are the T cells in
the tumors that belong to TCGA cluster II luminal subtype
[[66_TD$DIFF]76], which could explain why cluster IV tumors are
somewhat less sensitive to immune checkpoint blockade.
It could be noteworthy that atezolizumab providedmaximal
benefit in a portion of the tumors that belonged to the
subtype that had been previously defined as being more
resistant to conventional chemotherapy [[63_TD$DIFF] 7,73]. In other
words, if the findings are validated, cisplatin-based chemo-
therapy and atezolizumab may produce clinical benefit in
complementary populations of patients.
3.5. Genomic alterations in molecular subtypes of MIBC
Given past observations in the molecular subtypes in other
cancers, it seemed likely that the molecular subtypes of
bladder cancer would contain distinct mutations and CNAs.
To test this hypothesis, we established a collaboration to
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Fig. 2 – Enrichment of significantly mutated genes and CNAs in the UNC subty
versus luminal tumors, and the results are displayed as percentages of tumors
correspond to chromosomal amplification unless specifically identified as dele
between subtypes. CNA = copy number aberration; UNC = University of North Cassign the tumors from the complete TCGA RNA-seq dataset
(n = 408) to subtypes using the classifiers developed at UNC,
MD Anderson, and Lund University. We also obtained the
subtype calls from the original TCGAmarker paper [ [15_TD$DIFF] 7] and
the subsequent analyses performed by the group at the
Broad Institute[68_TD$DIFF] (n = 238 tumors) [ [5_TD$DIFF]18], in order to compare
the calls with thosemade by our groups. We then examined
each subtype for its content of specific DNA mutations
(n = 391, available from Firehose [https://gdac.
broadinstitute.org/]) and CNAs (n = 404, available from
cBioportal [http://www.cbioportal.org/]). The results con-
firmed the patterns of subtype overlap noted in a recent
study [[59_TD$DIFF]69]. Specifically, the UNC basal-like subtype
contained almost all the MD Anderson basal, Lund SCCL,
and Broad basal tumors, and TCGA clusters III and IV (Fig. 1),
strongly supporting the consensus view that the basal/SCC-
like subtype is consistently observed in muscle-invasive
tumors [[69_TD$DIFF]78]. The UNC basal-like subtype also contained half
of the MD Anderson p53-like, most of the Lund uroB and
infiltrated, and all the Broad immune undifferentiated
tumors (Fig. 1). The UNC luminal subtype contained almost
all the MD Anderson luminal tumors, half of the MD
Anderson p53-like tumors, most of the Lund GU and uroA
tumors, most of the Broad luminal immune and luminal
tumors, and TCGA clusters I and II (Fig. 1).
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CNAs in TCGA’s whole exome sequencing dataset in
Firehose and cBioportal, respectively, and examined their
prevalence in the UNC basal-like and luminal subtypes
(Supplementary Fig. 1 and 2). Included among them were
alterations that were enriched in the breast cancer intrinsic
subtypes (TP53, RB1, ERBB2, and PIK3CA), genes that
displayed different mutation frequencies in NMIBCs versus
MIBCs (FGFR3, KDM6A, and STAG2), and genes that encode
for mRNAs that were enriched in basal or luminal MIBCs
(EGFR, PPARG, GATA3, ELF3, and ERBB3). Consistent with the
overall hypothesis, several of the alterations were signifi-
cantly enriched in either UNC basal-like or luminal cancers
(Fig. 2).
We then investigated whether creating further subdivi-
sions of the UNC molecular subtypes caused additional
patterns of enrichment as had been documented previously
[ [59_TD$DIFF]69]. Although the mutations and CNAs that were enriched
in the UNC basal-like and luminal MIBCs were also enriched
in the MD Anderson basal and luminal MIBCs, isolating the
p53-like tumors did not further enhance enrichment
(Fig. 3). Similarly, no mutations or CNAs were specifically
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between subtypes. CNA = copy number aberration; MDA = MD Anderson. * p < 0enriched in the Lund infiltrated tumors as compared with
the other Lund subtypes in this panel (Fig. 4). Therefore, it
appears that the biology of these infiltrated tumors is
dictated less by genetic influences than by other factors,
such as the tumor microenvironment, explaining why their
subtype membership was somewhat unstable [[70_TD$DIFF]67,69]. On
the other hand, subdividing the UNC basal-like and luminal
tumors into the other Lund subtypes yielded additional and
highly informative patterns of mutation and CNA enrich-
ment. The uroA and uroB tumors were both highly enriched
with activating FGFR3 mutations [ [71_TD$DIFF]65,66,69], and the uroB
tumors also contained a higher number of CDKN2A (p16)
deletions (Fig. 4). The uroA and uroB tumors were also
characterized by fewer RB1mutations, and the uroB tumors
could be distinguished from the uroA tumors by their
content of PIK3CA, NFE2L2, ERBB2, and ERBB3 mutations
(Fig. 4). Finally, the Lund subdivision of the UNC luminal
MIBCs into the GU and uroA subtypes yielded additional
informative patterns of mutation and CNA enrichment
[[59_TD$DIFF]69]. The GU tumors could be distinguished from the uroA
tumors by the absence of activating FGFR3mutations and by
the presence of TP53 and ERCC2 mutations, RB1 deletions,
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(Fig. 4).
4. Conclusions
Molecular subtypes of bladder cancer are enriched with
specific genetic alterations. As recognized previously [ [57_TD$DIFF]68],
basal/SCC-like MIBCs frequently contain RB1 mutations, a
property that they share with basal-like breast cancers
[[72_TD$DIFF] 9,80]. Basal/SCC-likeMIBCs are also enrichedwithNFE2L2
mutations, which have also been identified in lung and head
and neck squamous cancers [ [18_TD$DIFF]21,22]. Luminal tumors
contain more alterations in FGFR3 and KDM6A (also known
as UTX) genes that are more commonly mutated in NMIBCs
as compared with that in MIBCs [1]. These observations
support the emerging conclusion that FGFR3 mutations
mark the luminal MIBCs that correspond to the papillary
NMIBCs that have progressed to become muscle invasive.
Alterations affecting several transcription factors that
appear to play important roles in urothelial terminal
differentiation [ [73_TD$DIFF]81,82] (PPARG, GATA3, RXRA, and ELF3)were also enriched in luminal cancers. Biological effects of
these alterations will need to be explored in future
functional studies.
The Lund subclassifications divide the UNC/MD Ander-
son/TCGA basal/SCC-like and luminal subtypes in ways that
have important biological and clinical implications. Al-
though they cluster together with the squamous/basal
tumors in the UNC, MD Anderson, and TCGA classifications,
the genetic alterations in the uroB tumors more closely
resemble those present in the luminal uroA subtype,
supporting the conclusion that they represent progressed
versions of the uroA cancers. The precise mechanisms that
cause them to appear more ‘‘basal’’ (at the molecular level,
and also in terms of their enrichment with squamous
histological features and lethality) will be very interesting;
their relatively high content of RB1 and NFE2L2 mutations
suggests possible mechanisms. The existence of uroB
tumors also suggests that basal versus luminal subtype
class ‘‘switching’’ is possible. Clinically, it will be interesting
to determinewhether the uroA and uroB tumors are equally
sensitive to FGFR inhibitors.
E U RO P E AN URO L OGY 7 2 ( 2 0 1 7 ) 3 5 4 – 3 6 5 363The subdivision in the UNC/MD Anderson/TCGA luminal
tumors that is created by the Lund classifier also appears to
be extremely important. It is very interesting that the GU
and uroA tumors are enriched with somewhat mutually
exclusive patterns of mutations and CNAs involving key
luminal genes (PPARG/GATA3 vs FGFR3). Overall, more of the
top genes in the GU tumorswere affected by CNAs than they
were in the other molecular subtypes. The fact that GU
tumors are enriched with ERCC2 mutations is also
noteworthy. It will be interesting to determine their
relationships to cigarette smoking [[19_TD$DIFF]23] and relative
sensitivities to NAC [[32_TD$DIFF] 5]. Given that ERCC2, RB1 [ [33_TD$DIFF] 6], and
ERBB2 [ [74_TD$DIFF]83] mutations and CNA levels in general [ [32_TD$DIFF] 5] have
been linked to chemosensitivity, it seems likely that
patients with GU tumors will obtain greater direct clinical
benefit from NAC than those who have uroA tumors.
It should be emphasized that our understanding of the
biological and clinical properties of the molecular subtypes
of bladder cancer is still fairly limited. Most of the available
genomic and associated clinical data were obtained
retrospectively, and the clinical follow-up is fairly short.
Although the total number of profiled bladder cancers is
increasing, it is relatively small, and challenges associated
with merging the data that have been and continue to be
generated on different genomic platforms make generating
meta-datasets difficult. Preclinical studies implicating
different cells of origin in the formation of papillary [ [75_TD$DIFF]84]
and nonpapillary [[76_TD$DIFF]56] cancers provide possible explana-
tions for the origins of basal and luminal bladder cancers,
but their relevance to human carcinogenesis remains
unclear. The specific effects of most of the DNA alterations
that have been identified in bladder cancers need to be
explored much more deeply, presumably in preclinical
models, to determine whether subtype context is important
for their effects. The new information provided by TCGA and
other groups will enable laboratory scientists to create
models that more accurately capture important aspects of
the genomic heterogeneity observed in patients.
We do not yet know whether molecular subtype
membership is a stable, ‘‘intrinsic’’ feature of a given
tumor. Bioinformatic analyses have already demonstrated
that membership in the p53-like/infiltrated/TCGA cluster II
subtype is relatively unstable, and we have demonstrated
that luminal tumors often become p53-like after NAC
[ [58_TD$DIFF]67]. These observations could explain why TCGA cluster II
membership is not even more strongly associated with
response to immune checkpoint blockade than has been
observed in recently completed clinical trials [ [65_TD$DIFF]75]. In
addition, as noted above, the uroB subtype may establish
a precedent for luminal-to-basal subtype ‘‘switching’’ in
bladder cancer. Muscle-invasive tumors can be multifocal,
and our collaborators are currently performing whole-
organ mapping studies to determine whether all these
multifocal tumors belong to the same subtype (B. Czerniak,
personal communication). NMIBCs are prone to recurrence,
and it will be important to perform longitudinal studies to
determine how often subtype membership is maintained in
these recurrences. Ongoing studies are performing deep
genomic characterizations of metastases, and it will beinteresting to see whether primary tumors and metastases
always belong to the same subtype. Finally, additional
comparisons of the DNA alterations in and subtype
membership of tumors collected before and after neoadju-
vant therapies, and where possible, systemic therapy for
metastatic disease, must still be performed to determine
whether subtype membership is stable. This information
has important implications for prognostication and sub-
type-based therapy.
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